Britto J A, Moore R L, Evans R D, Hayward R D, Jones B M
The Craniofacial Centre, Great Ormond Street Hospital for Children, London, United Kingdom.
J Neurosurg. 2001 Oct;95(4):660-73. doi: 10.3171/jns.2001.95.4.0660.
Heterogeneous mutations in the fibroblast growth factor receptor 2 gene (FGFR2) cause a range of craniosynostosis syndromes. The specificity of the Apert syndrome-affected cranial phenotype reflects its narrow mutational range: 98% of cases of Apert syndrome result from an Ser252Trp or Pro253Arg mutation in the immunoglobulin-like (Ig)IIIa extracellular subdomain of FGFR2. In contrast, a broad range of mutations throughout the extracellular domain of FGFR2 causes the overlapping cranial phenotypes of Pfeiffer and Crouzon syndromes and related craniofacial dysostoses.
In this paper the expression of FGFR1, the IgIIIa/c and IgIIIa/b isoforms of FGFR2, and FGFR3 is investigated in Apert syndrome (P253R mutation)- and Pfeiffer syndrome (C278F mutation)-affected fetal cranial tissue and is contrasted with healthy human control tissues. Both FGFR1 and FGFR3 are normally expressed in the differentiated osteoblasts of the periosteum and osteoid, in domains overlapped by that of FGFR2, which widely include preosseous cranial mesenchyme. Expression of FGFR2, however, is restricted to domains of advanced osseous differentiation in both Apert syndrome- and Pfeiffer syndrome-affected cranial skeletogenesis in the presence of fibroblast growth factor (FGF)2, but not in the presence of FGF4 or FGF7. Whereas expression of the FGFR2-IgIIIa/b (KGFR) isoform is restricted in normal human cranial osteogenesis, there is preliminary evidence that KGFR is ectopically expressed in Pfeiffer syndrome-affected cranial osteogenesis.
Contraction of the FGFR2-IgIIIa/c (BEK) expression domain in cases of Apert syndrome- and Pfeiffer syndrome-affected fetal cranial ossification suggests that the mutant activation of this receptor, by ligand-dependent or ligand-independent means, results in negative autoregulation. This phenomenon, resulting from different mechanisms in the two syndromes, offers a model by which to explain differences in their cranial phenotypes.
成纤维细胞生长因子受体2基因(FGFR2)的异质性突变会引发一系列颅缝早闭综合征。Apert综合征所影响的颅骨表型具有特异性,这反映出其突变范围较窄:98%的Apert综合征病例是由FGFR2免疫球蛋白样(Ig)IIIa细胞外亚结构域中的Ser252Trp或Pro253Arg突变所致。相比之下,FGFR2细胞外结构域中的广泛突变会导致Pfeiffer综合征和Crouzon综合征以及相关颅面骨发育不全的重叠颅骨表型。
本文研究了FGFR1、FGFR2的IgIIIa/c和IgIIIa/b异构体以及FGFR3在Apert综合征(P253R突变)和Pfeiffer综合征(C278F突变)所影响的胎儿颅骨组织中的表达情况,并与健康人体对照组织进行对比。FGFR1和FGFR3通常在骨膜和成骨样细胞的分化成骨细胞中表达,其表达区域与FGFR2的表达区域重叠,FGFR2的表达区域广泛包括骨前颅间充质。然而,在成纤维细胞生长因子(FGF)2存在的情况下,FGFR2的表达仅限于Apert综合征和Pfeiffer综合征所影响的颅骨骨生成中高级骨分化的区域,而在FGF4或FGF7存在时则不表达。虽然FGFR2-IgIIIa/b(KGFR)异构体的表达在正常人类颅骨骨生成中受到限制,但有初步证据表明KGFR在Pfeiffer综合征所影响的颅骨骨生成中异位表达。
在Apert综合征和Pfeiffer综合征所影响的胎儿颅骨骨化病例中,FGFR2-IgIIIa/c(BEK)表达域的收缩表明,该受体通过配体依赖性或配体非依赖性方式的突变激活会导致负向自动调节。这一由两种综合征中不同机制导致的现象,为解释它们颅骨表型的差异提供了一个模型。